GlassScriptPhysician profile
Maria A Incer Obando
NPI 1194777078
$7,523.63
in general payments reported to CMS, 2019-2025
33 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2021: $1,086 · 2022: $1,267 · 2023: $2,409 · 2024: $1,250 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,452 · Education: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,451.91 |
| Education | $1,336.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cambridge Interventional LLC | $1,312.50 | 2023 | Crf |
| Amgen INC. | $823.90 | 2019-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $779.98 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $448.59 | 2023-2025 | Jardiance |
| Esperion Therapeutics, INC. | $429.73 | 2021-2023 | Nexletol |
| Dexcom, INC. | $379.87 | 2021-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $365.82 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Xeris Pharmaceuticals, INC. | $281.35 | 2022-2025 | Recorlev |
| Ascendis Pharma Endocrinology INC | $246.80 | 2023-2025 | Yorvipath |
| Corcept Therapeutics | $242.60 | 2024-2025 | Korlym |
| Lilly USA, LLC | $220.44 | 2021-2024 | Jardiance, Lyumjev |
| Abbvie INC. | $216.22 | 2021-2025 | |
| Abbott Laboratories | $201.80 | 2021 | |
| Amneal Pharmaceuticals LLC | $156.14 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $155.70 | 2021-2023 | Steglatro, Steglujan, Verquvo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $150.14 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $145.80 | 2023 | Xarelto |
| Janssen Pharmaceuticals, INC | $124.55 | 2022 | |
| Alexion Pharmaceuticals, INC. | $124.20 | 2025 | Ultomiris |
| Shire North American Group INC | $121.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $120.41 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2019 | |
| Mannkind Corporation | $98.55 | 2022 | |
| Beta Bionics, INC. | $64.63 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Recordati_rare_diseases_inc. | $44.12 | 2024 | Isturisa, Signifor Lar |
| Novartis Pharmaceuticals Corporation | $39.62 | 2023 | |
| Neurocrine Biosciences, INC. | $24.04 | 2025 | |
| Grt US Holding, INC. | $21.77 | 2022 | |
| Pfizer INC. | $20.20 | 2023 | |
| Nevro Corp. | $17.58 | 2024 | Senza |
| Sanofi Pasteur INC. | $15.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.22 | 2021 | |
| Horizon Therapeutics Plc | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Incer Obando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.